These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 26308197)

  • 1. New evidence in the treatment of overactive bladder.
    Brown ET; Martin L; Dmochowski RR
    Curr Opin Obstet Gynecol; 2015 Oct; 27(5):366-72. PubMed ID: 26308197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on Overactive Bladder Therapeutic Options.
    Babin CP; Catalano NT; Yancey DM; Pearl NZ; Koonce EM; Ahmadzadeh S; Shekoohi S; Cornett EM; Kaye AD
    Am J Ther; 2024 Jul-Aug 01; 31(4):e410-e419. PubMed ID: 37171410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on the treatment of overactive bladder.
    Dmochowski RR; Gomelsky A
    Curr Opin Urol; 2011 Jul; 21(4):286-90. PubMed ID: 21499104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of novel therapies for overactive bladder.
    Mayr CA; Shepherd JP
    Expert Rev Pharmacoecon Outcomes Res; 2014 Aug; 14(4):527-35. PubMed ID: 24809616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of overactive bladder symptoms beyond antimuscarinics: current and future therapies.
    Ellsworth P
    Postgrad Med; 2012 May; 124(3):16-27. PubMed ID: 22691895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An overview of treatment of overactive bladder syndrome in women.
    Allahdin S; Oo N
    J Obstet Gynaecol; 2012 Apr; 32(3):217-21. PubMed ID: 22369391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment patterns and costs among patients with OAB treated with combination oral therapy, sacral nerve stimulation, percutaneous tibial nerve stimulation, or onabotulinumtoxinA in the United States.
    Kraus SR; Shiozawa A; Szabo SM; Qian C; Rogula B; Hairston J
    Neurourol Urodyn; 2020 Nov; 39(8):2206-2222. PubMed ID: 32827230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The management of overactive bladder: percutaneous tibial nerve stimulation, sacral nerve stimulation, or botulinum toxin?
    Tubaro A; Puccini F; De Nunzio C
    Curr Opin Urol; 2015 Jul; 25(4):305-10. PubMed ID: 26049873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New therapies in the treatment of overactive bladder.
    Yeo EK; Hashim H; Abrams P
    Expert Opin Emerg Drugs; 2013 Sep; 18(3):319-37. PubMed ID: 23885696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overactive Bladder.
    White N; Iglesia CB
    Obstet Gynecol Clin North Am; 2016 Mar; 43(1):59-68. PubMed ID: 26880508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Overactive Bladder-Wet Syndrome on Female Sexual Function: A Systematic Review and Meta-Analysis.
    Balzarro M; Rubilotta E; Mancini V; Trabacchin N; Oppezzi L; Li Marzi V; Fusco F; Serati M
    Sex Med Rev; 2019 Oct; 7(4):565-574. PubMed ID: 31326358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overactive bladder syndrome - management and treatment options.
    Arnold J; McLeod N; Thani-Gasalam R; Rashid P
    Aust Fam Physician; 2012 Nov; 41(11):878-83. PubMed ID: 23145420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding clinic options for overactive bladder.
    Bartley JM; Blum ES; Sirls LT; Peters KM
    Curr Urol Rep; 2013 Dec; 14(6):541-8. PubMed ID: 23812967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of OAB in those over age 65.
    Natalin R; Lorenzetti F; Dambros M
    Curr Urol Rep; 2013 Oct; 14(5):379-85. PubMed ID: 23922134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Actual treatment of overactive bladder and urge urinary incontinence.
    Cornu JN
    Minerva Urol Nefrol; 2013 Mar; 65(1):21-35. PubMed ID: 23538308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of refractory OAB in the non-neurogenic patient.
    Wadie BS
    Curr Urol Rep; 2014 Sep; 15(9):438. PubMed ID: 25015301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Overactive bladder-which treatment when?].
    Pannek J
    Urologe A; 2017 Dec; 56(12):1532-1538. PubMed ID: 29043374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Behavioral therapies for overactive bladder: making sense of the evidence.
    Milne JL
    J Wound Ostomy Continence Nurs; 2008; 35(1):93-101; quiz 102-3. PubMed ID: 18199944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overactive bladder: diagnosis and management.
    Robinson D; Cardozo L
    Maturitas; 2012 Feb; 71(2):188-93. PubMed ID: 22197347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.